An FDA vaccine advisory panel voted unanimously this week to recommend a monovalent XFG vaccine for COVID-19 shots in the 2026-2027 season, marking the latest twist in the ongoing effort to match vaccines with evolving viral strains. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 8 to 0, with one abstention, signaling strong but not universal confidence in the decision to target the variant currently dominant across the United States.
The choice reflects a careful calculus balancing immediate threat against emerging uncertainty. The XFG variant is the most common strain circulating in the U.S. right now, making it the logical target for next year's shots. Yet the decision also revealed real tension among vaccine experts about whether the panel is making the best long-term choice. Some worry about missing an opportunity to broaden vaccine effectiveness against variants like BA.3.2—sometimes called "cicada"—which, while still relatively uncommon in America, became the dominant strain in Germany and South Africa.
All three major vaccine manufacturers presented data showing that XFG vaccines generate high levels of neutralizing antibodies against the JN.1 family of variants. However, that protection comes with a tradeoff: the vaccines have more limited neutralization of BA.3.2 lineages. When the companies tested BA.3.2 vaccines instead, those formulations offered better protection against BA.3.2 but at the cost of lower neutralization against JN.1 variants. There is no vaccine that excels against both.
The debate hinged partly on manufacturing realities. Stanley Perlman, MD, PhD, of the University of Iowa, who chaired the meeting, noted that the World Health Organization had recommended the LP.8.1 strain for next year's vaccines—a choice that "would have been fine." But Sanofi, the only manufacturer with a protein subunit vaccine (Nuvaxovid, acquired from Novavax), does not have an LP.8.1 option ready. Because LP.8.1 and XFG are very similar, choosing XFG was "a good choice" for the U.S., Perlman said. Diversifying the vaccine portfolio mattered.
Dr. Hana El Sahly of Baylor College of Medicine in Houston abstained from voting, raising a cautionary note. She pointed out that existing data showed the XFG vaccine is essentially interchangeable with LP.8.1 in the breadth and strength of immune response. "We might be missing the opportunity to expand the breadth of response to the NB.1.8.1 and BA.3.2 variants that are increasing, especially in children who are engines of transmission of respiratory viruses," she said. She warned that if BA.3.2 acquires mutations and rises in frequency over the next few months, the chosen vaccine strategy could prove insufficient.
The meeting also surfaced a deeper worry: the timing of vaccine strain selection. Late spring decisions may not align well with COVID's actual seasonal patterns, which include both late summer and early fall surges in addition to winter peaks. Surveillance remains a weak link. "The stronger our systems are, the better we'll be in position to make decisions for variants that are going to continue to emerge," said Dr. Flor Munoz-Rivas of Baylor.
On a brighter note, the epidemiological picture has improved. CDC data presented at the meeting showed that hospitalization rates for the 2025-2026 season are lower than any previous year, with rates declining year over year. Overall vaccine effectiveness against hospitalization reached 58% through six months following vaccination. Those gains suggest that even as the virus evolves, public health responses are gradually gaining ground.